CD44 and HIV-1 infection: Our CRISPR/Cas9-induced clones were selected based on reduced TRN-SR2 expression and on resistance to HIV-1 infection, which eventually resulted in the selection of a TRN-SR2/IN interface mutant in clone 15.15.